Volume 24, Number 7—July 2018
Research
Registry Cohort Study to Determine Risk for Multiple Sclerosis after Vaccination for Pandemic Influenza A(H1N1) with Arepanrix, Manitoba, Canada
Salaheddin M. Mahmud
, Songul Bozat-Emre, Luiz C. Mostaço-Guidolin, and Ruth Ann Marrie
, Songul Bozat-Emre, Luiz C. Mostaço-Guidolin, and Ruth Ann Marrie
Table 1
Cohort characteristics by vaccination status, Manitoba, Canada, 2009–2012*
| Variable | No. (%) persons |
||||||
|---|---|---|---|---|---|---|---|
| Adjuvanted A(H1N1)pdm09 |
Unadjuvanted A(H1N1)pdm09 |
TIV alone | Unvaccinated | ||||
| Alone | And TIV | Alone | And TIV | ||||
| Total |
267,539 (100) |
61,239 (100) |
10,592 (100) |
1,977 (100) |
144,594 (100) |
485,941 (100) |
|
| Age group, y | |||||||
| <14 | 83,097 (31.1) | 10,206 (16.7) | 1,245 (11.8) | 109 (5.5) | 4,915 (3.4) | 99,463 (20.5) | |
| 15–34 | 62,261 (23.3) | 12,637 (20.6) | 4,717 (44.5) | 679 (34.3) | 7,094 (4.9) | 92,008 (18.9) | |
| 35–44 | 38,401 (14.4) | 9,272 (15.1) | 1,835 (17.3) | 363 (18.4) | 6,463 (4.5) | 51,795 (10.7) | |
| 45–54 | 39,958 (14.9) | 12,018 (19.6) | 1,452 (13.7) | 389 (19.7) | 12,696 (8.8) | 74,454 (15.3) | |
| >55 |
43,822 (16.4) |
17,106 (27.9) |
1,343 (12.7) |
437 (22.1) |
113,426 (78.4) |
168,221 (34.6) |
|
| Sex | |||||||
| F |
144,461 (54.0) |
31,081 (50.8) |
7,352 (69.4) |
1,194 (60.4) |
82,868 (57.3) |
266,956 (54.9) |
|
| Urban residence |
146,256 (54.7) |
41,916 (68.4) |
6,202 (58.6) |
1,604 (81.1) |
96,605 (66.8) |
292,583 (60.2) |
|
| Income quintile | |||||||
| Q1 (lowest) | 53,269 (19.9) | 9,766 (15.9) | 1,803 (17.0) | 279 (14.1) | 27,899 (19.3) | 92,147 (19.0) | |
| Q2 | 47,036 (17.6) | 11,066 (18.1) | 1,833 (17.3) | 355 (18.0) | 27,593 (19.1) | 91,214 (18.8) | |
| Q3 | 48,257 (18.0) | 10,976 (17.9) | 1,766 (16.7) | 358 (18.1) | 28,037 (19.4) | 91,542 (18.8) | |
| Q4 | 50,592 (18.9) | 12,454 (20.3) | 2,373 (22.4) | 447 (22.6) | 27,167 (18.8) | 95,379 (19.6) | |
| Q5 (highest) | 62,320 (23.3) | 15,602 (25.5) | 2,613 (24.7) | 503 (25.4) | 25,103 (17.4) | 101,411 (20.9) | |
| Cannot be calculated |
6,065 (2.3) |
1,375 (2.2) |
204 (1.9) |
35 (1.8) |
8,795 (6.1) |
14,248 (2.9) |
|
| Immunosuppressed | 11,541 (4.3) | 4,028 (6.6) | 322 (3.0) | 78 (3.9) | 20,990 (14.5) | 33,561 (6.9) | |
| Autoimmune diseases | 6,680 (2.5) | 2,669 (4.4) | 197 (1.9) | 45 (2.3) | 10,179 (7.0) | 17,661 (3.6) | |
| Any chronic diseases | 18486 (6.9) | 7,485 (12.2) | 364 (3.4) | 96 (4.9) | 42,909 (29.7) | 65,158 (13.4) | |
| Pregnant, % of all 15–49-year-old females |
2,184 (3.1) |
355 (2.4) |
2,857 (50.6) |
330 (40.4) |
816 (7.4) |
5,160 (4.9) |
|
| High priority for A(H1N1)pdm09 vaccine | 142,909 (53.4) | 25,652 (41.9) | 6,200 (58.5) | 683 (34.5) | 59,165 (40.9) | 230,948 (47.5) | |
| High priority for TIV | 42,207 (15.8) | 12,958 (21.2) | 3,231 (30.5) | 419 (21.2) | 105,557 (73.0) | 158,565 (32.6) | |
| Received 2008–09 TIV | 41,896 (15.7) | 22,231 (36.3) | 1,237 (11.7) | 542 (27.4) | 109,107 (75.5) | 42,071 (8.7) | |
| Received pneumococcal vaccine | 49,203 (18.4) | 11,554 (18.9) | 286 (2.7) | 64 (3.2) | 87,552 (60.6) | 86,261 (17.8) | |
*A(H1N1)pdm09, pandemic influenza A(H1N1) strain; Q, quintile; TIV, trivalent influenza vaccine.
Page created: June 18, 2018
Page updated: June 18, 2018
Page reviewed: June 18, 2018
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.